Please use this identifier to cite or link to this item:
Title: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Issue Date: Jan-2015
Citation: J. Natl. Cancer Inst..2015 Jan;(107)1:366
Abstract: The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality reduction for the men screened in the intervention arm and a 23% negative impact on the life-years gained because of quality of life. However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, overdiagnosis, and costs.
PMID: 25505238
Rights: openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
PMC4296196.pdf891.66 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.